A JAMA Neurology study demonstrates that concomitant levetiracetam and DOAC therapy in adults with epilepsy is associated with nearly double the risk of thromboembolic events and higher mortality.
Most Recent Articles
Mitigating Reperfusion Injury and Infarct Size With Dexrazoxane in Acute STEMI
The SHIELD-MI trial demonstrates that peri-procedural intravenous dexrazoxane reduces intramyocardial hemorrhage by 68% and decreases infarct size in acute STEMI patients.
Modeling Diastolic Dysfunction in HFpEF Using Human iPSC-Derived Engineered Heart Tissues
A novel human iPSC-derived heart tissue model replicates HFpEF diastolic dysfunction and reveals how SGLT2 inhibitors reduce cardiac inflammation through endothelial pathways.
Phase 1a Trial Demonstrates Sustained Lipid Reduction via CTX310 Gene Editing
A Phase 1a trial shows that a single infusion of CRISPR-Cas9 therapy CTX310 achieves 12-month reductions in LDL cholesterol and triglycerides without serious adverse events.
Neurological and Systemic Complications of Varicella Zoster Virus Reactivation: A Comprehensive Review
A Nature Reviews Disease Primers study highlights that latent varicella zoster virus reactivation can drive severe stroke and neurovascular disease without causing a shingles rash.